Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-09-23 am EDT
9.950 HKD   -3.40%
09/06China to Exclude Medical Devices From Bulk-Buying Program
MT
09/01VENUS MEDTECH ANNOUNCES 2022 INTERIM RESULTS : quality and efficiency improvement, profitability focus, rapid progress in global presence
AQ
09/01Venus Medtech (Hangzhou)'s H1 Loss Widens 76.8%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. Appoints Martin B. Leon as the Global Principal Investigator of RDN Innovative System

07/27/2021 | 04:34am EDT

The board of Venus Medtech (Hangzhou) Inc. announced that Professor Martin B. Leon has been appointed as the global Principal Investigator ("PI") for the new generation of renal artery denervation ("RDN") innovative system developed by Renaly Ltd. ("Renaly"), controlling subsidiary. Meanwhile, he also serves as the director of Columbia Interventional Cardiovascular Care, director of the Cardiac Catheterization Laboratory, and the director of the Executive Board of the Columbia Structural Heart & Valve Center. In addition, he is also the founder and chairman of the global Transcatheter Cardiovascular Therapeutics ("TCT") conference. In the field of RDN, Professor Martin and his team have been serving as the PI for clinical trials for several innovative systems including Medtronic's Symplicity SpyralTM Renal Denervation System and ReCor Medical's ParadiseTM Ultrasonic Denervation System, both of which were awarded Breakthrough Device Designation by the U.S Food and Drug Administration in 2020. The new generation of RDN innovative system is developed by Renaly. Its exclusive Dual-Mode Ultrasound Technology (DMUT) Platform can realize non-contact continuous ablation treatment with real-time monitoring function, which significantly reduces the occurrence of various problems such as insufficient nerve ablation or vascular damage caused by uncontrollable ablation while achieving accurate and efficient ablation, in order to shift the treatment paradigm to more predictable outcomes and simplify the operation procedure flow to ultimately improve the safety and efficacy of ablation procedures.


© S&P Capital IQ 2021
All news about VENUS MEDTECH (HANGZHOU) INC.
09/06China to Exclude Medical Devices From Bulk-Buying Program
MT
09/01VENUS MEDTECH ANNOUNCES 2022 INTERIM : quality and efficiency improvement, profitability f..
AQ
09/01Venus Medtech (Hangzhou)'s H1 Loss Widens 76.8%
MT
08/31Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/31Venus Medtech Inc. Announces Change of Employee Representative Supervisor and Chairpers..
CI
07/13China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's..
CI
07/13Chinese Regulator Approves Venus Medtech's Valve Replacement System
MT
06/22First American Patient Treated with VenusP-Valve™ Under Compassionate Use
AQ
06/22Venus Medtech Inc. Announces First American Patient Treated with VenusP-Valve Under Com..
CI
04/13Venus Medtech Completes First-in-Human Study of Bioprosthetic Heart Valve Product
MT
More news
Financials
Sales 2022 515 M 72,2 M 72,2 M
Net income 2022 -387 M -54,3 M -54,3 M
Net cash 2022 2 450 M 344 M 344 M
P/E ratio 2022 -10,1x
Yield 2022 -
Capitalization 3 956 M 555 M 555 M
EV / Sales 2022 2,93x
EV / Sales 2023 2,41x
Nbr of Employees 1 039
Free-Float 73,5%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 9,03 CNY
Average target price 18,69 CNY
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Hai Yue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Min Shao Chairman-Supervisory Board
Hou-Sen Lim Chief Technology & Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VENUS MEDTECH (HANGZHOU) INC.-66.39%555
STRYKER CORPORATION-22.62%78 286
SMITH & NEPHEW PLC-22.34%9 549
INSPIRE MEDICAL SYSTEMS, INC.-25.42%4 940
AXONICS, INC.16.50%3 205
GLAUKOS CORPORATION13.39%2 397